Advanced search
Publication Cover
Immunotherapy Volume 2, 2010 - Issue 3
Submit an article Journal homepage
139
Views
0
CrossRef citations to date
0
Altmetric
Review

Immunotherapy Following Hematopoietic Stem Cell Transplantation: Potential for Synergistic Effects

Myriam N Bouchlaka1 Department of Microbiology & Immunology, University of Nevada, Reno, NV, USA
,
Doug Redelman2 Department of Physiology & Cell Biology, University of Nevada, Reno, NV, USA
&
William J Murphy3 Department of Dermatology & Internal Medicine, University of California – Davis, Sacramento, CA95816, USA.Tel.: +1 916 703 5662 Fax: +1 916 703 [email protected]
Pages 399-418 | Published online: 10 May 2010

Bibliography

  • Kurnick NB , MontanoA, GerdesJC, FederBH: Preliminary observations on the treatment of postirradiation hematopoietic depression in man by the infusion of stored autogenous bone marrow.Ann. Intern. Med.49(5) , 973–986 (1958).
  • Varas F , BernadA, BuerenJA: Granulocyte colony-stimulating factor mobilizes into peripheral blood the complete clonal repertoire of hematopoietic precursors residing in the bone marrow of mice.Blood88(7) , 2495–2501 (1996).
  • Plerixafor: AMD3100, AMD3100, JM 3100, SDZ SID 791. Drugs RD8(2) , 113–119 (2007).
  • Cashen AF , NerviB, DiPersioJ: AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent.Future Oncol.3(1) , 19–27 (2007).
  • Uy GL , RettigMP, CashenAF: Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.Expert Opin. Biol. Ther.8(11) , 1797–1804 (2008).
  • Blaise D , KuentzM, FortanierCet al.: Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle.J. Clin. Oncol.18(3) , 537–546 (2000).
  • Schmitz N , BacigalupoA, HasencleverDet al.: Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation.Bone Marrow Transplant.21(10) , 995–1003 (1998).
  • Singhal S , PowlesR, KulkarniSet al.: Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation.Bone Marrow Transplant.25(5) , 501–505 (2000).
  • Heldal D , TjonnfjordG, BrinchLet al.: A randomised study of allogeneic transplantation with stem cells from blood or bone marrow.Bone Marrow Transplant.25(11) , 1129–1136 (2000).
  • Powles R , MehtaJ, KulkarniSet al.: Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial.Lancet355(9211) , 1231–1237 (2000).
  • Schmitz N , DregerP, SuttorpMet al.: Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor).Blood85(6) , 1666–1672 (1995).
  • Appelbaum FR : Haematopoietic cell transplantation as immunotherapy.Nature411(6835) , 385–389 (2001).
  • Thomas ED : Karnofsky memorial lecture. Marrow transplantation for malignant diseases.J. Clin. Oncol.1(9) , 517–531 (1983).
  • Cairo MS , and Wagner JE: Placental and/or umbilical cord blood: an alternative source of hematopoietic stem cells for transplantation. Blood90(12) , 4665–4678 (1997).
  • Rubinstein P , CarrierC, ScaradavouAet al.: Outcomes among 562 recipients of placental-blood transplants from unrelated donors.N. Engl. J. Med.339(22) , 1565–1577 (1998).
  • Wagner JE , KernanNA, SteinbuchM, BroxmeyerHE, GluckmanE: Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease.Lancet346(8969) , 214–219 (1995).
  • MacMillan ML , WeisdorfDJ, BrunsteinCGet al.: Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors.Blood113(11) , 2410–2415 (2009).
  • Verneris MR , BrunsteinCG, BarkerJet al.: Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units.Blood114(19) , 4293–4299 (2009).
  • Aversa F : Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States.Bone Marrow Transplant.41(5) , 473–481 (2008).
  • Aversa F , BernemanZN, LocatelliFet al.: Fourth International Workshop on Haploidentical Transplants, Naples, Italy, July 8–10, 2004.Blood Cells Mol. Dis.33(3) , 159–175 (2004).
  • Aversa F , TerenziA, FeliciniRet al.: Haploidentical stem cell transplantation for acute leukemia.Int. J. Hematol.76(Suppl.) 1165–1168 (2002).
  • Aversa F , VelardiA, TabilioA, ReisnerY, MartelliMF: Haploidentical stem cell transplantation in leukemia.Blood Rev.15(3) , 111–119 (2001).
  • Gassas A , SungL, SaundersEF, DoyleJ: Graft-versus-leukemia effect in hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia: significantly lower relapse rate in unrelated transplantations.Bone Marrow Transplant.40(10) , 951–955 (2007).
  • Khouri IF , SalibaRM, GiraltSAet al.: Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.Blood98(13) , 3595–3599 (2001).
  • Schetelig J , ThiedeC, BornhauserMet al.: Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia.Ann. Hematol.81(Suppl. 2) , S47–S48 (2002).
  • Schetelig J , ThiedeC, BornhauserMet al.: Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.J. Clin. Oncol.21(14) , 2747–2753 (2003).
  • Weiden PL , FlournoyN, ThomasEDet al.: Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.N. Engl. J. Med.300(19) , 1068–1073 (1979).
  • Deeg HJ , StorbR: Acute and chronic graft-versus-host disease: clinical manifestations, prophylaxis, and treatment.J. Natl Cancer Inst.76(6) , 1325–1328 (1986).
  • Ratanatharathorn V , AyashL, LazarusHM, FuJ, UbertiJP: Chronic graft-versus-host disease: clinical manifestation and therapy.Bone Marrow Transplant.28(2) , 121–129 (2001).
  • Kansu E : The pathophysiology of chronic graft-versus-host disease.Int. J. Hematol.79(3) , 209–215 (2004).
  • Tyndall A , DazziF: Chronic GVHD as an autoimmune disease.Best Pract. Res. Clin. Haematol.21(2) , 281–289 (2008).
  • Bryson JS , JenningsCD, CaywoodBE, DixAR, LoweryDM, KaplanAM: Enhanced graft-versus-host disease in older recipient mice following allogeneic bone marrow transplantation.Bone Marrow Transplant.19(7) , 721–728 (1997).
  • Remberger M , KumlienG, AschanJet al.: Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Biol. Blood Marrow Transplant.8(12) , 674–682 (2002).
  • Fischer AC , HessAD: Age-related factors in cyclosporine-induced syngeneic graft-versus-host disease: regulatory role of marrow-derived T lymphocytes.J. Exp. Med.172(1) , 85–94 (1990).
  • Parmar S , Del Lima M, Zou Y et al.: Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood114(14) , 2884–2887 (2009).
  • Anasetti C , BeattyPG, StorbRet al.: Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma.Hum. Immunol.29(2) , 79–91 (1990).
  • Antin JH , FerraraJL: Cytokine dysregulation and acute graft-versus-host disease.Blood80(12) , 2964–2968 (1992).
  • Ferrara JL , LevineJE, ReddyP, HollerE: Graft-versus-host disease.Lancet373(9674) , 1550–1561 (2009).
  • Loiseau P , BussonM, BalereMLet al.: HLA Association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival.Biol. Blood Marrow Transplant.13(8) , 965–974 (2007).
  • Antin JH : Clinical practice. Long-term care after hematopoietic-cell transplantation in adults.N. Engl. J. Med.347(1) , 36–42 (2002).
  • Couriel D , CalderaH, ChamplinR, KomanduriK: Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management.Cancer101(9) , 1936–1946 (2004).
  • Barnes DW , LoutitJF: Treatment of murine leukaemia with x-rays and homologous bone marrow. II.Br. J. Haematol.3(3) , 241–252 (1957).
  • Bar BM , SchattenbergA, MensinkEJet al.: Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation.J. Clin. Oncol.11(3) , 513–519 (1993).
  • Marmont AM , HorowitzMM, GaleRPet al.: T-cell depletion of HLA-identical transplants in leukemia.Blood78(8) , 2120–2130 (1991).
  • Mitsuyasu RT , ChamplinRE, GaleRPet al.: Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial.Ann. Intern. Med.105(1) , 20–26 (1986).
  • Goldman JM , GaleRP, HorowitzMMet al.: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.Ann. Intern. Med.108(6) , 806–814 (1988).
  • Marks DI , HughesTP, SzydloRet al.: HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome.Br. J. Haematol.81(3) , 383–390 (1992).
  • Couriel DR , SalibaRM, GiraltSet al.: Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation.Biol. Blood Marrow Transplant.10(3) , 178–185 (2004).
  • Sorror ML , MarisMB, SandmaierBMet al.: Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia.J. Clin. Oncol.23(16) , 3819–3829 (2005).
  • Alyea EP , KimHT, HoVet al.: Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.Blood105(4) , 1810–1814 (2005).
  • Vodanovic-Jankovic S , HariP, JacobsP, KomorowskiR, DrobyskiWR: NF-κB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145.Blood107(2) , 827–834 (2006).
  • Welniak LA , BlazarBR, MurphyWJ: Immunobiology of allogeneic hematopoietic stem cell transplantation.Annu. Rev. Immunol.25139–25170 (2007).
  • Ferrara JL : Novel strategies for the treatment and diagnosis of graft-versus-host-disease.Best Pract. Res. Clin. Haematol.20(1) , 91–97 (2007).
  • Ferrara JL , CookeKR, PanL, KrengerW: The immunopathophysiology of acute graft-versus-host-disease.Stem Cells14(5) , 473–489 (1996).
  • Sun Y , TawaraI, ToubaiT, ReddyP: Pathophysiology of acute graft-versus-host disease: recent advances.Transl. Res.150(4) , 197–214 (2007).
  • Tsukada N , KobataT, AizawaY, YagitaH, OkumuraK: Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation.Blood93(8) , 2738–2747 (1999).
  • Krenger W , HillGR, FerraraJL: Cytokine cascades in acute graft-versus-host disease.Transplantation64(4) , 553–558 (1997).
  • Murphy WJ , WelniakLA, TaubDDet al.: Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice.J. Clin. Invest.102(9) , 1742–1748 (1998).
  • Basara N , BlauWI, KiehlMGet al.: Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient.Transplant. Proc.30(8) , 4087–4089 (1998).
  • Basara N , KiehlMG, BlauWet al.: Mycophenolate mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience.Transplant. Proc.33(3) , 2121–2123 (2001).
  • Bolanos-Meade J , JacobsohnDA, MargolisJet al.: Pentostatin in steroid-refractory acute graft-versus-host disease.J. Clin. Oncol.23(12) , 2661–2668 (2005).
  • Maraninchi D , GluckmanE, BlaiseDet al.: Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias.Lancet2(8552) , 175–178 (1987).
  • Wagner JE , DonnenbergAD, NogaSJet al.: Lymphocyte depletion of donor bone marrow by counterflow centrifugal elutriation: results of a Phase I clinical trial.Blood72(4) , 1168–1176 (1988).
  • Drobyski WR , AshRC, CasperJTet al.: Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia.Blood83(7) , 1980–1987 (1994).
  • Pavletic SZ , CarterSL, KernanNAet al.: Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation.Blood106(9) , 3308–3313 (2005).
  • Storb R : Bone marrow transplantation.Transplant. Proc.27(5) , 2649–2652 (1995).
  • Feugier P , TheveninS, BillotMet al.: Comparison of T cell depletion strategies from bone marrow, umbilical cord and peripheral blood using five separation systems.Hematol. Cell Ther.39(2) , 67–73 (1997).
  • Hale G , XiaMQ, TigheHP, DyerMJ, WaldmannH: The CAMPATH-1 antigen (CDw52).Tissue Antigens35(3) , 118–127 (1990).
  • Waldmann H , and Hale G: CAMPATH: from concept to clinic. Philos. Trans. R Soc. Lond. B. Biol. Sci.360(1461) , 1707–1711 (2005).
  • Hale G , WaldmannH: Risks of developing Epstein–Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users.Blood91(8) , 3079–3083 (1998).
  • Chu YW , GressRE: Murine models of chronic graft-versus-host disease: insights and unresolved issues.Biol. Blood Marrow Transplant.14(4) , 365–378 (2008).
  • Reddy P , NegrinR, HillGR: Mouse models of bone marrow transplantation.Biol. Blood Marrow Transplant.14(1 Suppl. 1) , 129–135 (2008).
  • Storb R , YuC, WagnerJLet al.: Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation.Blood89(8) , 3048–3054 (1997).
  • Atkinson K , ShulmanHM, DeegHJet al.: Acute and chronic graft-versus-host disease in dogs given hemopoietic grafts from DLA-nonidentical littermates. Two distinct syndromes.Am. J. Pathol.108(2) , 196–205 (1982).
  • Kolb H , SaleGE, LernerKG, StorbR, ThomasED: Pathology of acute graft-versus-host disease in the dog. An autopsy study of ninety-five dogs.Am. J. Pathol.96(2) , 581–594 (1979).
  • Mestas J , HughesCC: Of mice and not men: differences between mouse and human immunology.J. Immunol.172(5) , 2731–2738 (2004).
  • Stevens JC , BanksGT, FestingMF, FisherEM: Quiet mutations in inbred strains of mice.Trends Mol. Med.13(12) , 512–519 (2007).
  • Taft RA , DavissonM, WilesMV: Know thy mouse.Trends Genet.22(12) , 649–653 (2006).
  • Champlin R , HoW, GajewskiJet al.: Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation.Blood76(2) , 418–423 (1990).
  • Truitt RL , AtasoyluAA: Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow.Bone Marrow Transplant.8(1) , 51–58 (1991).
  • Dazzi F , SzydloRM, GoldmanJM: Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand.Exp. Hematol.27(10) , 1477–1486 (1999).
  • Martin PJ , RowleySD, AnasettiCet al.: A Phase I–II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrowfor HLA-mismatched unrelated recipients.Blood94(7) , 2192–2199 (1999).
  • Rosenberg SA , PackardBS, AebersoldPMet al.: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.N. Engl. J. Med.319(25) , 1676–1680 (1988).
  • Rosenberg SA , YangJC, TopalianSLet al.: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.JAMA271(12) , 907–913 (1994).
  • Rosenberg SA , YannelliJR, YangJCet al.: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.J. Natl Cancer Inst.86(15) , 1159–1166 (1994).
  • Rosenberg SA , AebersoldP, CornettaKet al.: Gene transfer into humans – immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction.N. Engl. J. Med.323(9) , 570–578 (1990).
  • Dudley ME , YangJC, SherryRet al.: Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.J. Clin. Oncol.26(32) , 5233–5239 (2008).
  • Rosenberg SA , DudleyME: Adoptive cell therapy for the treatment of patients with metastatic melanoma.Curr. Opin. Immunol.21(2) , 233–240 (2009).
  • Morgan RA , DudleyME, WunderlichJRet al.: Cancer regression in patients after transfer of genetically engineered lymphocytes.Science314(5796) , 126–129 (2006).
  • Gattinoni L , FinkelsteinSE, KlebanoffCAet al.: Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.J. Exp. Med.202(7) , 907–912 (2005).
  • Overwijk WW , TheoretMR, FinkelsteinSEet al.: Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.J. Exp. Med.198(4) , 569–580 (2003).
  • Rosenberg SA , RestifoNP, YangJC, MorganRA, DudleyME: Adoptive cell transfer: a clinical path to effective cancer immunotherapy.Nat. Rev. Cancer8(4) , 299–308 (2008).
  • Wrzesinski C , RestifoNP: Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy.Curr. Opin. Immunol.17(2) , 195–201 (2005).
  • Berry LJ , MoellerM, DarcyPK: Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells.Tissue Antigens74(4) , 277–289 (2009).
  • Sadelain M , BrentjensR, RiviereI: The promise and potential pitfalls of chimeric antigen receptors.Curr. Opin. Immunol.21(2) , 215–223 (2009).
  • Wrzesinski C , PaulosCM, GattinoniLet al.: Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells.J. Clin. Invest.117(2) , 492–501 (2007).
  • Cooke KR , HillGR, CrawfordJMet al.: Tumor necrosis factor-α production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease.J. Clin. Invest.102(10) , 1882–1891 (1998).
  • Hill GR , FerraraJL: The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation.Blood95(9) , 2754–2759 (2000).
  • Liang H , LiaoC, QiZet al.: Rapamycin or tacrolimus alone fails to resist cardiac allograft accelerated rejection mediated by alloreactive CD4+ memory T cells in mice.Transpl. Immunol.22(3–4) , 128–136 (2010).
  • Bingaman AW , FarberDL: Memory T cells in transplantation: generation, function, and potential role in rejection.Am. J. Transplant.4(6) , 846–852 (2004).
  • Verneris MR , KaramiM, BakerJ, JayaswalA, NegrinRS: Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells.Blood103(8) , 3065–3072 (2004).
  • Kim HM , LimJ, KangJSet al.: Inhibition of human cervical carcinoma growth by cytokine-induced killer cells in nude mouse xenograft model.Int. Immunopharmacol.9(3) , 375–380 (2009).
  • Nishimura R , BakerJ, BeilhackAet al.: In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity.Blood112(6) , 2563–2574 (2008).
  • Ljunggren HG , KarreK: In search of the ‘missing self‘: MHC molecules and NK cell recognition.Immunol. Today11(7) , 237–244 (1990).
  • Thompson JA , ShulmanKL, BenyunesMCet al.: Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.J. Clin. Oncol.10(6) , 960–968 (1992).
  • Trinchieri G : Biology of natural killer cells.Adv. Immunol.47187–47376 (1989).
  • Koh CY , WelniakLA, MurphyWJ: Adoptive cellular immunotherapy: NK cells and bone marrow transplantation.Histol. Histopathol.15(4) , 1201–1210 (2000).
  • Uhrberg M , ValianteNM, ShumBPet al.: Human diversity in killer cell inhibitory receptor genes.Immunity7(6) , 753–763 (1997).
  • Lanier LL : NK cell recognition.Annu. Rev. Immunol.23 , 225–274 (2005).
  • Bennett M : Rejection of marrow allografts: importance of H-2 homozygosity of donor cells.Transplantation14(3) , 289–298 (1972).
  • Cudkowicz G , BennettM: Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F1 hybrid mice.J. Exp. Med.134(6) , 1513–1528 (1971).
  • Yu YY , KumarV, BennettM: Murine natural killer cells and marrow graft rejection.Annu. Rev. Immunol.10 , 189–213 (1992).
  • Cudkowicz G , BennettM: Peculiar immunobiology of bone marrow allografts. I. Graft rejection by irradiated responder mice.J. Exp. Med.134(1) , 83–102 (1971).
  • Natarajan K , DimasiN, WangJ, MariuzzaRA, MarguliesDH: Structure and function of natural killer cell receptors: multiple molecular solutions to self, nonself discrimination.Annu. Rev. Immunol.20 , 853–885 (2002).
  • Yu YY , GeorgeT, DorfmanJR, RolandJ, KumarV, BennettM: The role of Ly49A and 5E6(Ly49C) molecules in hybrid resistance mediated by murine natural killer cells against normal T cell blasts.Immunity4(1) , 67–76 (1996).
  • Asai O , LongoDL, TianZGet al.: Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.J. Clin. Invest.101(9) , 1835–1842 (1998).
  • Ruggeri L , AversaF, MartelliMF, VelardiA: Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self.Immunol. Rev.214 , 202–218 (2006).
  • Ruggeri L , CapanniM, UrbaniEet al.: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.Science295(5562) , 2097–2100 (2002).
  • Passweg JR , TichelliA, Meyer-MonardSet al.: Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation.Leukemia18(11) , 1835–1838 (2004).
  • Koh CY , RaziuddinA, WelniakLA, BlazarBR, BennettM, MurphyWJ: NK inhibitory-receptor blockade for purging of leukemia: effects on hematopoietic reconstitution.Biol. Blood Marrow Transplant.8(1) , 17–25 (2002).
  • Ljunggren HG , MalmbergKJ: Prospects for the use of NK cells in immunotherapy of human cancer.Nat. Rev. Immunol.7(5) , 329–339 (2007).
  • Romagne F , AndreP, SpeePet al.: Preclinical characterization of 1–7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.Blood114(13) , 2667–2677 (2009).
  • Sola C , AndreP, LemmersCet al.: Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo.Proc. Natl Acad. Sci. USA106(31) , 12879–12884 (2009).
  • Shevach EM , ThorntonA, Suri-PayerE: T lymphocyte-mediated control of autoimmunity.Novartis Found. Symp.215 , 200–211; discussion 211–230 (1998).
  • Battaglia M , RoncaroloMG: Induction of transplantation tolerance via regulatory T cells.Inflamm. Allergy Drug Targets5(3) , 157–165 (2006).
  • Nguyen VH , ZeiserR, NegrinRS: Role of naturally arising regulatory T cells in hematopoietic cell transplantation.Biol. Blood Marrow Transplant.12(10) , 995–1009 (2006).
  • Yong Z , ChangL, MeiYX, YiL: Role and mechanisms of CD4+CD25+ regulatory T cells in the induction and maintenance of transplantation tolerance.Transpl. Immunol.17(2) , 120–129 (2007).
  • Sakaguchi S , SakaguchiN, AsanoM, ItohM, TodaM: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.J. Immunol.155(3) , 1151–1164 (1995).
  • Graca L , CobboldSP, WaldmannH: Identification of regulatory T cells in tolerated allografts.J. Exp. Med.195(12) , 1641–1646 (2002).
  • Gregori S , CasoratiM, AmuchasteguiS, SmiroldoS, DavalliAM, AdoriniL: Regulatory T cells induced by 1 α,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance.J. Immunol.167(4) , 1945–1953 (2001).
  • Hara M , KingsleyCI, NiimiMet al.: IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo.J. Immunol.166(6) , 3789–3796 (2001).
  • Hoffmann P , ErmannJ, EdingerM, FathmanCG, StroberS: Donor-type CD4+CD25+ regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation.J. Exp. Med.196(3) , 389–399 (2002).
  • Blazar BR , TaylorPA, NoelleRJ, ValleraDA: CD4+ T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses.J. Clin. Invest.102(3) , 473–482 (1998).
  • Godfrey WR , SpodenDJ, GeYGet al.: Cord blood CD4+CD25+-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function.Blood105(2) , 750–758 (2005).
  • Edinger M , HoffmannP, ErmannJet al.: CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.Nat. Med.9(9) , 1144–1150 (2003).
  • Jones SC , MurphyGF, KorngoldR: Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.Biol. Blood Marrow Transplant.9(4) , 243–256 (2003).
  • Trenado A , CharlotteF, FissonSet al.: Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia.J. Clin. Invest.112(11) , 1688–1696 (2003).
  • Hill GR , CrawfordJM, CookeKR, BrinsonYS, PanL, FerraraJL: Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines.Blood90(8) , 3204–3213 (1997).
  • Hill GR , TeshimaT, GerbitzAet al.: Differential roles of IL-1 and TNF-α on graft-versus-host disease and graft versus leukemia.J. Clin. Invest.104(4) , 459–467 (1999).
  • van Bekkum DW , RoodenburgJ, HeidtPJ, van der Waaij D: Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J. Natl Cancer Inst.52(2) , 401–404 (1974).
  • Teshima T , OrdemannR, ReddyPet al.: Acute graft-versus-host disease does not require alloantigen expression on host epithelium.Nat. Med.8(6) , 575–581 (2002).
  • Duffner UA , MaedaY, CookeKRet al.: Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease.J. Immunol.172(12) , 7393–7398 (2004).
  • Shlomchik WD , CouzensMS, TangCBet al.: Prevention of graft versus host disease by inactivation of host antigen-presenting cells.Science285(5426) , 412–415 (1999).
  • Reddy V , IturraspeJA, TzolasAC, Meier-KriescheHU, ScholdJ, WingardJR: Low dendritic cell count after allogeneic hematopoietic stem cell transplantation predicts relapse, death, and acute graft-versus-host disease.Blood103(11) , 4330–4335 (2004).
  • Auffermann-Gretzinger S , LossosIS, VayntrubTAet al.: Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients.Blood99(4) , 1442–1448 (2002).
  • Chakraverty R , SykesM: The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia.Blood110(1) , 9–17 (2007).
  • Edinger M , PowrieF, ChakravertyR: Regulatory mechanisms in graft-versus-host responses.Biol. Blood Marrow Transplant.15(Suppl. 1) , 2–6 (2008).
  • Matte CC , LiuJ, CormierJet al.: Donor APCs are required for maximal GVHD but not for GVL.Nat. Med.10(9) , 987–992 (2004).
  • Anderson BE , McNiffJM, JainD, BlazarBR, ShlomchikWD, ShlomchikMJ: Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ.Blood105(5) , 2227–2234 (2005).
  • Pahl HL : Activators and target genes of Rel/NF-κB transcription factors.Oncogene18(49) , 6853–6866 (1999).
  • Siebenlist U , FranzosoG, BrownK: Structure, regulation and function of NF-kappa B.Annu. Rev. Cell Biol.10405–10455 (1994).
  • Dejardin E : The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development.Biochem. Pharmacol.72(9) , 1161–1179 (2006).
  • Richardson PG , MitsiadesC, HideshimaT, AndersonKC: Bortezomib: proteasome inhibition as an effective anticancer therapy.Annu. Rev. Med.57 , 33–47 (2006).
  • Markovina S , CallanderNS, O‘ConnorSLet al.: Bortezomib-resistant nuclear factor-κB activity in multiple myeloma cells.Mol. Cancer Res.6(8) , 1356–1364 (2008).
  • Kane RC , BrossPF, FarrellAT, PazdurR: Velcade: US FDA approval for the treatment of multiple myeloma progressing on prior therapy.Oncologist8(6) , 508–513 (2003).
  • Sun K , WelniakLA, Panoskaltsis-MortariAet al.: Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.Proc. Natl Acad. Sci. USA101(21) , 8120–8125 (2004).
  • Sun K , LiM, SayersTJ, WelniakLA, MurphyWJ: Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation.Blood112(4) , 1522–1529 (2008).
  • Sayers TJ , BrooksAD, KohCYet al.: The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.Blood102(1) , 303–310 (2003).
  • Koreth J , StevensonKE, KimHTet al.: Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.Blood114(18) , 3956–3959 (2009).
  • Lonial S , WallerEK, RichardsonPGet al.: Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.Blood106(12) , 3777–3784 (2005).
  • Reddy P , MaedaY, HotaryKet al.: Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.Proc. Natl Acad. Sci. USA101(11) , 3921–3926 (2004).
  • Marks P , RifkindRA, RichonVM, BreslowR, MillerT, KellyWK: Histone deacetylases and cancer: causes and therapies.Nat. Rev. Cancer1(3) , 194–202 (2001).
  • Butler LM , AgusDB, ScherHIet al.: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.Cancer Res.60(18) , 5165–5170 (2000).
  • Cohen LA , MarksPA, RifkindRAet al.: Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors.AntiCancer Res.22(3) , 1497–1504 (2002).
  • Leoni F , ZalianiA, BertoliniGet al.: The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines.Proc. Natl Acad. Sci. USA99(5) , 2995–3000 (2002).
  • Kelly WK , RichonVM, O‘ConnorOet al.: Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.Clin. Cancer Res.9(10 Pt 1) , 3578–3588 (2003).
  • Linsley PS , GreeneJL, BradyW, BajorathJ, LedbetterJA, PeachR: Human B7–1 (CD80) and B7–2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.Immunity1(9) , 793–801 (1994).
  • Linsley PS , GreeneJL, TanPet al.: Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.J. Exp. Med.176(6) , 1595–1604 (1992).
  • van der Merwe PA , BodianDL, DaenkeS, LinsleyP, DavisSJ: CD80 (B7–1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics.J. Exp. Med.185(3) , 393–403 (1997).
  • Walunas TL , LenschowDJ, BakkerCYet al.: CTLA-4 can function as a negative regulator of T cell activation.Immunity1(5) , 405–413 (1994).
  • Carreno BM , BennettF, ChauTAet al.: CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression.J. Immunol.165(3) , 1352–1356 (2000).
  • Krummel MF , AllisonJP: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.J. Exp. Med.182(2) , 459–465 (1995).
  • Blazar BR , TaylorPA, LinsleyPS, ValleraDA: In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice.Blood83(12) , 3815–3825 (1994).
  • Blazar BR , TaylorPA, Panoskaltsis-MortariA, SharpeAH, ValleraDA: Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells.J. Immunol.162(11) , 6368–6377 (1999).
  • Fife BT , BluestoneJA: Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.Immunol. Rev.224166–182 (2008).
  • Greenwald RJ , FreemanGJ, SharpeAH: The B7 family revisited.Annu. Rev. Immunol.23515–23548 (2005).
  • Alderson KL , ZhouQ, BernerVet al.: Regulatory and conventional CD4+ T cells show differential effects correlating with PD-1 and B7-H1 expression after immunotherapy.J. Immunol.180(5) , 2981–2988 (2008).
  • Ozkaynak E , WangL, GoodearlAet al.: Programmed death-1 targeting can promote allograft survival.J. Immunol.169(11) , 6546–6553 (2002).
  • Blazar BR , CarrenoBM, Panoskaltsis-MortariAet al.: Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-γ-dependent mechanism.J. Immunol.171(3) , 1272–1277 (2003).
  • Blazar BR , SharpeAH, ChenAIet al.: Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients.Blood101(9) , 3741–3748 (2003).
  • Jung U , FoleyJE, ErdmannAAet al.: Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy.Biol. Blood Marrow Transplant.12(9) , 905–918 (2006).
  • Foley JE , JungU, MieraAet al.: Ex vivo rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL-4-dependent mechanism.J. Immunol.175(9) , 5732–5743 (2005).
  • Kappel LW , GoldbergGL, KingCGet al.: IL-17 contributes to CD4-mediated graft-versus-host disease.Blood113(4) , 945–952 (2009).
  • Yi T , ZhaoD, LinCLet al.: Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease.Blood112(5) , 2101–2110 (2008).
  • Couriel D , SalibaR, HicksKet al.: Tumor necrosis factor-α blockade for the treatment of acute GVHD.Blood104(3) , 649–654 (2004).
  • Chiang KY , AbhyankarS, BridgesK, GodderK, Henslee-DowneyJP: Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease.Transplantation73(4) , 665–667 (2002).
  • Przepiorka D , KernanNA, IppolitiCet al.: Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease.Blood95(1) , 83–89 (2000).
  • Wolff D , RoesslerV, SteinerBet al.: Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept.Bone Marrow Transplant.35(10) , 1003–1010 (2005).
  • Yanik G , HellerstedtB, CusterJet al.: Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.Biol. Blood Marrow Transplant.8(7) , 395–400 (2002).
  • Bartholomew A , SturgeonC, SiatskasMet al.: Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.Exp. Hematol.30(1) , 42–48 (2002).
  • Le Blanc K , TammikL, SundbergB, HaynesworthSE, RingdenO: Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex.Scand. J. Immunol.57(1) , 11–20 (2003).
  • Tian Y , DengYB, HuangYJ, WangY: Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.Immunol. Invest.37(1) , 29–42 (2008).
  • Barrett AJ , and Le Blanc K: Prophylaxis of acute GVHD: manipulate the graft or the environment? Best Pract. Res. Clin. Haematol.21(2) , 165–176 (2008).
  • Le Blanc K , FrassoniF, BallLet al.: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a Phase II study.Lancet371(9624) , 1579–1586 (2008).
  • Ning H , YangF, JiangMet al.: The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study.Leukemia22(3) , 593–599 (2008).
  • Karnoub AE , DashAB, VoAPet al.: Mesenchymal stem cells within tumour stroma promote breast cancer metastasis.Nature449(7162) , 557–563 (2007).
  • Gesundheit B , ShapiraMY, ResnickIBet al.: Successful cell-mediated cytokine-activated immunotherapy for relapsed acute myeloid leukemia after hematopoietic stem cell transplantation.Am. J. Hematol.84(3) , 188–190 (2009).
  • Huang XJ , LiuDH, LiuKYet al.: Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.Biol. Blood Marrow Transplant.15(2) , 257–265 (2009).
  • Kebriaei P , DetryMA, GiraltSet al.: Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.Blood110(9) , 3456–3462 (2007).
  • Poire X , ArtzA, LarsonRAet al.: Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.Leuk. Lymphoma50(1) , 85–91 (2009).
  • Wrench D , GribbenJG: Stem cell transplantation for non-Hodgkin‘s lymphoma.Hematol. Oncol. Clin. North Am.22(5) , 1051–1079, XI (2008).
  • Boyiadzis M , FoonKA, PavleticS: Hematopoietic stem cell transplantation for chronic lymphocytic leukemia: potential cure for an incurable disease.Expert Opin. Biol. Ther.7(12) , 1789–1797 (2007).
  • Gribben JG : Stem cell transplantation in chronic lymphocytic leukemia.Biol. Blood Marrow Transplant.15(Suppl. 1) , 53–58 (2008).
  • Laport GG , SandmaierBM, StorerBEet al.: Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.Biol. Blood Marrow Transplant.14(2) , 246–255 (2008).
  • Warlick ED , CiocA, DeforT, DolanM, WeisdorfD: Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.Biol. Blood Marrow Transplant.15(1) , 30–38 (2009).
  • Armand P , and Antin JH: Allogeneic stem cell transplantation for aplastic anemia. Biol. Blood Marrow Transplant.13(5) , 505–516 (2007).
  • Kim HJ , ParkCY, ParkYHet al.: Successful allogeneic hematopoietic stem cell transplantation using triple agent immunosuppression in severe aplastic anemia patients.Bone Marrow Transplant.31(2) , 79–86 (2003).
  • Min CK , KimDW, LeeJW, HanCW, MinWS, KimCC: Hematopoietic stem cell transplantation for high-risk adult patients with severe aplastic anemia; reduction of graft failure by enhancing stem cell dose.Haematologica86(3) , 303–310 (2001).
  • Bourquin JP , ThornleyI, NeubergDet al.: Favorable outcome of allogeneic hematopoietic stem cell transplantation for relapsed or refractory acute promyelocytic leukemia in childhood.Bone Marrow Transplant.34(9) , 795–798 (2004).
  • Friedrich W , and Muller SM: Allogeneic stem cell transplantation for treatment of immunodeficiency. Springer Semin. Immunopathol.26(1–2) , 109–118 (2004).
  • Gennery AR , CantAJ: Advances in hematopoietic stem cell transplantation for primary immunodeficiency.Immunol. Allergy Clin. North Am.28(2) , 439–456, X–XI (2008).
  • Gratwohl A : Allogeneic hematopoietic stem cell transplantation for severe autoimmune diseases.Autoimmunity41(8) , 673–678 (2008).
  • Nash RA : Allogeneic HSCT for autoimmune diseases: conventional conditioning regimens.Bone Marrow Transplant.32(Suppl. 1) , S77–S80 (2003).
  • Forrest DL , ThompsonK, NevillTJ, CoubanS, FernandezLA: Allogeneic hematopoietic stem cell transplantation for progressive follicular lymphoma.Bone Marrow Transplant.29(12) , 973–978 (2002).
  • Childs RW , ClaveE, TisdaleJ, PlanteM, HenselN, BarrettJ: Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect.J. Clin. Oncol.17(7) , 2044–2049 (1999).
  • Takahashi Y , ChildsRW: Nonmyeloablative transplantation: an allogeneic-based immunotherapy for renal cell carcinoma.Clin. Cancer Res.10(18 Pt 2) , S6353–S6359 (2004).
  • Nakashima Y , ShiratsuchiM, AbeYet al.: Sustained molecular remission by non-myeloablative stem cell transplantation after autologous hematopoietic stem cell transplantation in a patient with multiple myeloma.Leuk. Lymphoma46(8) , 1217–1222 (2005).
  • Zeiser R , BertzH, SpyridonidisA, HouetL, FinkeJ: Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives.Bone Marrow Transplant.34(11) , 923–928 (2004).
  • Claviez A , SuredaA, SchmitzN: Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin‘s lymphoma.Bone Marrow Transplant.42(Suppl. 2) , S16–S24 (2008).
  • Vose JM , SharpG, ChanWCet al.: Autologous transplantation for aggressive non-Hodgkin‘s lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.J. Clin. Oncol.20(9) , 2344–2352 (2002).
  • Drabko K , ChomaM, Zaucha-PrazmoAet al.: Megachemotherapy and autologous hematopoietic stem cell transplantation in children with solid tumours excluding neuroblastoma – experience of Polish paediatric centres.Med. Wieku Rozwoj.10(3 Pt 1) , 785–792 (2006).
  • Manilay JO , SykesM: Natural killer cells and their role in graft rejection.Curr. Opin. Immunol.10(5) , 532–538 (1998).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.